These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30518828)

  • 21. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
    Wolf C; Garding A; Filarsky K; Bahlo J; Robrecht S; Becker N; Zucknick M; Rouhi A; Weigel A; Claus R; Weichenhan D; Eichhorst B; Fischer K; Hallek M; Kuchenbauer F; Plass C; Döhner H; Stilgenbauer S; Lichter P; Mertens D
    Int J Cancer; 2018 Jan; 142(2):322-333. PubMed ID: 28921505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
    Yu J; Chen L; Cui B; Wu C; Choi MY; Chen Y; Zhang L; Rassenti LZ; Widhopf Ii GF; Kipps TJ
    Leukemia; 2017 Jun; 31(6):1333-1339. PubMed ID: 27904138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term growth potential of cryopreserved B chronic lymphocytic leukemia cells in suspension and in semisolid medium.
    Vilpo J; Vilpo L
    Leukemia; 2001 Jun; 15(6):992-4. PubMed ID: 11417491
    [No Abstract]   [Full Text] [Related]  

  • 24. Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
    Skopelja-Gardner S; Jones JD; Hamilton BJ; Danilov AV; Rigby WFC
    J Immunol; 2017 Aug; 199(4):1275-1282. PubMed ID: 28710251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
    Moyo TK; Wilson CS; Moore DJ; Eischen CM
    Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
    Chartomatsidou E; Ntoufa S; Kotta K; Rovida A; Akritidou MA; Belloni D; Ferrero E; Trangas T; Stavroyianni N; Anagnostopoulos A; Rosenquist R; Ghia P; Papakonstantinou N; Stamatopoulos K
    Blood Adv; 2019 Jun; 3(12):1891-1896. PubMed ID: 31227476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The APRIL paradox in normal versus malignant B cell biology.
    van Attekum MH; Kater AP; Eldering E
    Cell Death Dis; 2016 Jun; 7(6):e2276. PubMed ID: 27336720
    [No Abstract]   [Full Text] [Related]  

  • 28. Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells.
    Parente-Ribes A; Skånland SS; Bürgler S; Os A; Wang D; Bogen B; Tjønnfjord GE; Taskén K; Munthe LA
    Haematologica; 2016 Feb; 101(2):e59-62. PubMed ID: 26589914
    [No Abstract]   [Full Text] [Related]  

  • 29. Phospho Flow Cytometry with Fluorescent Cell Barcoding for Single Cell Signaling Analysis and Biomarker Discovery.
    Skånland SS
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30346411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
    Rozovski U; Harris DM; Li P; Liu Z; Jain P; Ferrajoli A; Burger J; Thompson P; Jain N; Wierda W; Keating MJ; Estrov Z
    Leuk Lymphoma; 2018 Nov; 59(11):2686-2691. PubMed ID: 29465264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential leukocyte counting and immunophenotyping in cryopreserved ex vivo whole blood.
    Nemes E; Kagina BM; Smit E; Africa H; Steyn M; Hanekom WA; Scriba TJ
    Cytometry A; 2015 Feb; 87(2):157-65. PubMed ID: 25515205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia.
    Fiorcari S; Maffei R; Audrito V; Martinelli S; Ten Hacken E; Zucchini P; Grisendi G; Potenza L; Luppi M; Burger JA; Deaglio S; Marasca R
    Oncotarget; 2016 Oct; 7(40):65968-65981. PubMed ID: 27602755
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD40 ligand, Bcl-2 and apoptosis in B-chronic lymphocytic leukemia.
    Hussein OA; Omran AA; Elnaggar AM; Fathy A
    Egypt J Immunol; 2009; 16(2):27-36. PubMed ID: 22059351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
    Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
    Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of cryopreservation of peripheral blood mononuclear cells (PBMCs) on the variability of an antigen-specific memory B cell ELISpot.
    Trück J; Mitchell R; Thompson AJ; Morales-Aza B; Clutterbuck EA; Kelly DF; Finn A; Pollard AJ
    Hum Vaccin Immunother; 2014; 10(8):2490-6. PubMed ID: 25424961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation.
    Sánchez ML; Almeida J; Vidriales B; López-Berges MC; García-Marcos MA; Moro MJ; Corrales A; Calmuntia MJ; San Miguel JF; Orfao A
    Leukemia; 2002 Aug; 16(8):1460-9. PubMed ID: 12145686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
    Chanas-Larue A; Villalpando-Rodriguez GE; Henson ES; Johnston JB; Gibson SB
    Leuk Res; 2020 Sep; 96():106423. PubMed ID: 32712432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number.
    Podhorecka M; Goracy A; Szymczyk A; Kowal M; Ibanez B; Jankowska-Lecka O; Macheta A; Nowaczynska A; Drab-Urbanek E; Chocholska S; Jawniak D; Hus M
    Oncotarget; 2017 May; 8(21):34661-34669. PubMed ID: 28416773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the B-cell signalling pathway in CLL and MCL.
    Sharma SP
    Lancet Oncol; 2013 Aug; 14(9):e343. PubMed ID: 24058963
    [No Abstract]   [Full Text] [Related]  

  • 40. Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
    Palma M; Krstic A; Peña Perez L; Berglöf A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Höglund P; Kimby E; Österborg A; Månsson R; Smith CIE
    Br J Haematol; 2018 Oct; 183(2):212-224. PubMed ID: 30125946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.